ImmuCell Corporation
ICCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5,506 | $6,445 | $8,067 | $7,751 |
| % Growth | -14.6% | -20.1% | 4.1% | – |
| Cost of Goods Sold | $3,143 | $3,627 | $4,713 | $4,919 |
| Gross Profit | $2,363 | $2,818 | $3,354 | $2,832 |
| % Margin | 42.9% | 43.7% | 41.6% | 36.5% |
| R&D Expenses | $694 | $832 | $757 | $819 |
| G&A Expenses | $0 | $720 | $623 | $555 |
| SG&A Expenses | $1,649 | $1,417 | $1,480 | $1,391 |
| Sales & Mktg Exp. | $0 | $696 | $857 | $836 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,343 | $2,248 | $2,236 | $2,210 |
| Operating Income | $20 | $570 | $1,118 | $621 |
| % Margin | 0.4% | 8.8% | 13.9% | 8% |
| Other Income/Exp. Net | -$155 | -$66 | $331 | -$101 |
| Pre-Tax Income | -$135 | $504 | $1,449 | $521 |
| Tax Expense | $4 | $2 | $2 | $6 |
| Net Income | -$140 | $502 | $1,447 | $515 |
| % Margin | -2.5% | 7.8% | 17.9% | 6.6% |
| EPS | -0.02 | 0.056 | 0.16 | 0.058 |
| % Growth | -136% | -65.3% | 177.8% | – |
| EPS Diluted | -0.02 | 0.056 | 0.16 | 0.058 |
| Weighted Avg Shares Out | 9,046 | 9,031 | 8,981 | 8,935 |
| Weighted Avg Shares Out Dil | 9,046 | 9,031 | 8,981 | 8,935 |
| Supplemental Information | – | – | – | – |
| Interest Income | $41 | $48 | $37 | $25 |
| Interest Expense | $135 | $125 | $128 | $125 |
| Depreciation & Amortization | $679 | $668 | $676 | $674 |
| EBITDA | $544 | $1,297 | $2,242 | $1,320 |
| % Margin | 9.9% | 20.1% | 27.8% | 17% |